Navigation Links
Webcast Alert: Isis Pharmaceuticals and Genzyme Corporation to Present Mipomersen Phase 3 Data in HoFH During AHA
Date:11/11/2009

CARLSBAD, Calif., Nov. 11 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Genzyme Corporation (Nasdaq: GENZ) announce the following webcast:

    What:      Isis Pharmaceuticals and Genzyme Corporation to present
               mipomersen Phase 3 data in HoFH during the American Heart
               Association's 2009 Scientific Sessions in Orlando, FL

    When:      Tuesday, November 17, 2009, at 9:00 a.m. PT / 12:00 p.m. ET

    Where:     www.isispharm.com or www.genzyme.com

    How:       Live on the Internet.  Simply log on to one of our Web sites
               listed above.

    Isis Contacts:         Kristina Lemonidis (Investors)
                           (760) 603-2490

                           Amy Blackley, Ph.D. (Media)
                           (760) 603-2772

    Genzyme Contacts:      Leah Monteiro (Investors)
                           (617) 768-6602

                           Erin Emlock (Media)
                           (617) 768-6923

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com or www.genzyme.com.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic and severe neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

ABOUT GENZYME

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 11,000 employees in locations spanning the globe and 2008 revenues of $4.6 billion.

With many established products and services helping patients in approximately 100 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need.

Genzyme's press releases and other company information are available at www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

SOURCE Isis Pharmaceuticals, Inc.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
2. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
3. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
4. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
5. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) First Quarter 2008 Financial Results Call Set for May 6
6. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
7. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
8. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
9. Online Coverage of International AIDS Conference Includes Daily Webcasts, Podcasts and Interviews
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
11. Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 2017 A recent research report published by ... alone is expected to reach a value of $55.8 billion by ... with 28 states have legalized marijuana for medical uses. In 2016, ... , North Dakota , Ohio ... use the drug in medical applications such as chemotherapies and pain ...
(Date:2/27/2017)... , Feb 27, 2017 Period October – December 2016 ... Operating result amounted to SEK -16.4 (-6.4) million Result ... share (-0.22) before and after dilution Cash flow from operating ... ... SEK 0.4 (0.4) million Operating result amounted to SEK -39.5 ...
(Date:2/24/2017)... Research and Markets has announced the addition ... Industry Forecast to 2025" report to their offering. ... The Global Wireless Health ... over the next decade to reach approximately $330.5 billion by 2025. ... for all the given segments on global as well as regional ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... ... not your typical author. She went from working as a movie extra on Bill Murray’s ... she isn’t swimming as a performing mermaid. , Her book isn’t typical either. In Carothers’ ... comedic look at the dysfunctions of God’s family, before Lucifer was sent to hell. ...
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed ... that despite scientific studies, the Center for Disease Control ( CDC ) and Infectious ... Kenneth B. Liegner, M.D. has compiled into a single volume a compelling argument ...
(Date:2/27/2017)... Francisco, CA (PRWEB) , ... February 27, 2017 ... ... clinic serving San Francisco and environs, is proud to announce an upgrade to ... information on the upgraded Yelp page on topics as diverse as Platelet Rich ...
(Date:2/26/2017)... ... February 26, 2017 , ... This is an ... world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p 1 (house ... is the globally recognised standard that sets out requirements for the technical competence ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... and reporting for healthcare organizations. This comprehensive and customizable solution empowers StaffBridge ... StaffBridge technology improves staffing efficiency, maximizes resource allocation, collects critical reporting data, ...
Breaking Medicine News(10 mins):